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Abstract
An implantable venous access device (IVAD) is routinely implanted for long-
term intravenous access. Despite its reliability and safety, catheter-related 
thrombosis remains the most common complication leading to irrevers-
ible dysfunction. Thrombosis incidence is underestimated because clini-
cal manifestation is usually asymptomatic. In this evidence-based review, 
we compared the distinct natural courses of four thrombosis locations 
with respect to the vessel (right atrium/central vein) or the catheter (intra-
lumen/fibrin sheath). Practical management recommendations are also 
proposed. Specifically, right atrial thrombus is a rare but life-threatening 
complication possibly leading to pulmonary embolism and cardiac arrest. 
Prompt surgical thrombectomy is strongly recommended, while medical 
treatments may be tried for pediatric patients with small to moderate-
sized thrombi. Central vein thrombosis is usually unnoticeable but, when 
left untreated, may progress to extensive obstruction of the superior vena 
cava. An antithrombotic agent, such as unfractionated or low-molecular-
weight heparin, is the first choice, while surgical intervention is not rec-
ommended due to lack of benefits. Intraluminal thrombotic occlusion 
(2–3%) and fibrin sheath formation (42–100%) are common etiologies 
associated with device malfunction. Both conditions are minor and can 
be readily resolved by fibrinolytic agents. Surgical removal of the device 
should only be considered after fibrinolytic agents have failed or therapy 
has been terminated because of its minor severity and high success rate 
of medical treatment. In conclusion, while IVAD is a durable and sustain-
able device that can provide a long-term intravenous route, identification 
of the exact thrombosis location will lead to rational treatment strate-
gies and thereby avoid unnecessary surgical intervention. [Tzu Chi Med J 
2007;19(4):207–219]
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1. Introduction
Implantable venous access devices (IVAD) have been 
widely used for cancer patients for long-term intrave-
nous access. In past decades, an IVAD has not only 
provided a safe, convenient, cosmetic and reliable 
system for access needs but has also improved the 
quality of life of oncologic patients. An IVAD opens up 
the possibilities of frequent, multiple and long-term 
intravenous injections, as well as blood aspirations. 
Such benefits allow patients to receive multiple treat-
ments, such as chemotherapeutic agents, antibiotics, 
total parenteral nutrition and blood products.
Despite its well-documented benefits, between 
10% and 50% of patients with an IVAD experience 
complications during treatment. Major complications, 
such as infection, thrombosis, occlusion, extravasa-
tion, migration and mechanical malfunction, may 
restrict the use of the device and thereby interrupt 
treatment courses. Of these complications, catheter-
related thrombosis (CRT) is known to be the most 
frequent complication. The clinical manifestations 
of CRT may range from asymptomatic vessel throm-
bosis to venous access failure or even symptomatic 
obstruction of major vessels, depending on the loca-
tion of the thrombus. When thrombi are located 
around the catheter tip or within the lumen, symp-
toms usually go unnoticed until injection difficulty or 
injectate extravasation occurs. However, if the throm-
bus extends to the superior vena cava (SVC) or the 
right atrial (RA) wall, life-threatening complications 
may occur. Although CRT is a complex problem with 
divergent outcomes, the incidence and management 
guidelines are unclear. The reported incidence of CRT 
varies from 2% to 20% because standard diagnostic 
tools and criteria are lacking. As shown in Table 1, 
most studies used apparent clinical symptoms and 
signs as their diagnostic tool without the aid of any 
objective evidence. Consequently, the specific type or 
location of the thrombosis was not documented [1]. 
In most of these CRT cases, thrombotic devices were 
removed without aggressive medical treatment [2–4] 
or with inappropriate treatment [2,5,6]. Without sci-
entific evidence for CRT management, once a throm-
bus occurs, most physicians will choose to remove 
the device to avoid complications. This high removal 
rate incurs treatment delay and limits the therapeu-
tic options of cancer patients. Only a few research-
ers have applied a scientific tool to investigate the 
etiology of CRT systematically. In these studies, there 
were higher occurrence rates and more variable CRT 
outcomes than in studies without standard diagnos-
tic criteria.
To date, we have yet to find any evidence-based 
review comparing IVAD CRT based on the specific 
location of thrombosis: RA thrombus, central vein 
thrombus, intraluminal thrombotic occlusion and 
fibrin sheath (Fig. 1). In this review, we undertook 
a systematic survey of the etiology and incidence 
of CRT, and primarily focused on issues related to 
the diagnosis and management of such thromboses. 
We systematically searched for reports in MEDLINE, 
EMBASE and the Cochrane Library, and classified 
each study into one of five levels of evidence (I to V) 
according to its importance and reliability. Based 
on this classification, we further investigated the risk 
and benefit analysis of medical management and 
traditional surgical revision.
2. Levels of evidence
Five levels of evidence were modified from the Oxford 
Centre and The Journal of Bone and Joint Surgery 
with respect to therapeutic, prognostic or diagnostic 
studies [7,8]. In order to identify the importance and 
reliability of the references, we noted the levels of 
evidence in each reference in our tables.
2.1. Therapeutic studies
• Level I: high-quality systematic review, randomized 
controlled trial with narrow confidence interval;
• Level II: lesser-quality systematic review of cohort 
studies (e.g., < 80% follow-up, no blinding or 
improper randomization);
• Level III: retrospective comparative study or case-
control study;
• Level IV: case series;
• Level V: expert opinion.
2.2. Prognostic studies
• Level I: high-quality prospective (all patients were 
enrolled at the same point in their disease with 
> 80% follow-up) systematic review study;
• Level II: lesser-quality prospective (patients 
enrolled at different points in their disease or 
< 80% follow-up) retrospective study or untreated 
control from a randomized controlled trial;
• Level III: absent in prognostic studies;
• Level IV: case series;
• Level V: expert opinion.
2.3. Diagnostic studies
• Level I: systematic review of prospective cohort 
studies with good follow-up;
• Level II: retrospective cohort study or poor follow-up;
• Level III: non-consecutive cohort study or very 
limited population;
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• Level IV: case-control study or study with poor ref-
erence standards;
• Level V: expert opinion.
3. Etiology and incidence
3.1. RA thrombus
IVAD-induced RA thrombus is clinically rare and silent 
but, when left untreated, will lead to life-threatening 
catastrophe. RA thrombus complicated with cardio-
genic shock, pulmonary embolism or cardiac arrest 
may result in a high mortality rate ranging from 28% 
to 31% [9–11]. Most patients with RA CRT had a high 
association with the catheter tip position in the RA 
[10,12–15]. In Gilon et al’s prospective study, all 
the RA thrombi were in the group with the catheter 
tip in the RA and 46% of this group developed RA 
thrombus within 6 months [13]. When the catheter 
tip is located within the RA, it may repeatedly brush 
against the atrial wall and induce intimal damage. The 
endothelium injury results in adherence of platelets, 
initiation of the coagulation cascade and thrombus 
formation. The severity of RA thrombus is much less 
in pediatric patients, leading to less hemodynamic 
compromise and pulmonary embolism [12]. The size 
of the thrombus was not significantly altered by the 
type of line or sepsis but showed a weak correla-
tion with line age [16]. RA CRT may also be closely 
associated with infection [16–21]. Staphylococcus 
and Candida albicans infection were often noted in 
patients with RA thrombus [16,19,20].
3.2. Central vein thrombus
Catheter-related central vein thrombosis (CVT) is a 
common, early-occurring and extensive complication, 
although it is usually asymptomatic and is an under-
estimated thrombotic complication in patients with 
IVAD. It is believed that the etiology of CVT is also 
related to endothelium injury. The movement of the 
catheter tip may cause intimal damage, which results 
in the formation of a mural thrombus that is attached 
to the wall of the vessel. In such conditions, the cath-
eter tip may sometimes become inlayed within this 
thrombus, inhibiting the function of the IVAD [22]. 
Most of these types of thrombus are silent and are 
not recognized until malfunction of the device or the 
occurrence of SVC syndromes.
The incidence of CVT ranged from 2% to 50%. 
The subclavian vein, which most catheters passed 
through, had the highest thrombosis rate [5,22]. Epi-
sodes may also occur in the internal jugular, axillary, 
brachiocephalic and azygous veins [23]. To investi-
gate the actual incidence of CVT, Glaser et al evalu-
ated the vessel patency of 24 oncologic children by 
contrast venography, which showed abnormalities 
in 12 patients (50%) [24]. Only three children had 
physical findings consistent with thrombosis, so the 
prevalence of silent thrombosis without signs or 
symptoms was nine out of 21 (43%). Therefore, the 
reported incidence appears to depend on whether 
the thrombosis is searched for systematically or only 
when it becomes symptomatic. It is clear that symp-
tomatic CVT is less common than asymptomatic CVT 
[4,24,25]. On average, 2.6–16% of patients with IVAD 
develop symptomatic CVT and 13–66% are asymp-
tomatic. For this reason, CVT is probably underre-
ported (Table 1). Several predisposing factors may 
influence the occurrence rate of CVT: the acceler-
ated coagulation system, the duration of the infusion 
time, the position of catheter insertion and its tip, the 
choice of chemotherapeutic agents, and the diagnos-
tic tools used [4,5]. Higher platelet counts and blood 
hemoglobin levels > 12.5 g/dL are also suspected to 
be risk factors. The catheter material and thickness 
may also determine the pathogenesis [23]. Catheters 
made of polyethylene have a higher thrombosis rate 
than those made of silicon, and it is believed that the 
thicker the catheter used, the greater the incidence 
of thrombosis [4]. There is evidence that indicates 
that there is a relationship between the thrombotic 
and infectious complications of catheters [23]. The 
site of implantation and the position of the catheter 
tip also have a strong correlation with the thrombosis 
rate. In Puel et al’s prospective trial, left-implanted 
RA
SVC
Fibrin sheath
Central vein
thrombus
Right atrial
thrombus
RV
Intraluminal
thrombotic
occlusion
Fig. 1 — Four locations of implantable venous access 
device-related thromboses. SVC = superior vena cava; RA = 
right atrium; RV = right ventricle.
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IVAD with the catheter tip in the upper half of the vena 
cava appears highly dangerous because the catheter 
tip knocks against the vessel wall at every heart-
beat and can cause chronic microtrauma, resulting 
in thrombosis occurring in up to 28.6% of patients 
[26,27]. Besides mechanical attack, another reason 
is toxicity and chemical attack by the infused drugs 
themselves. Advanced damage may also occur when 
the delivered drugs are in close contact with the 
injured vessel wall, progressing the mural thrombus 
to CVT. Therefore, right-implanted IVAD is safer than 
left-implanted IVAD; the catheter tip is located in the 
lower portion of the SVC and this is safer than being 
in the upper portion. Peripheral-implanted IVAD had 
a higher incidence than central-implanted IVAD [27]. 
CVT may be associated with deep venous thrombo-
sis (DVT) and SVC syndrome [4,24]. Clinically symp-
tomatic thrombosis can present in various ways, 
including catheter malfunction in association with 
arm swelling, neck or arm pain, and jugular venous 
distension. Subsequent symptoms include fever in 
the absence of infection, skin temperature changes 
and skin discoloration [23]. It is believed that CVT 
can also contribute to recurrence of the thrombus 
(4–19%), postphlebitic syndrome (5–25%), pulmonary 
embolism (8–15%) and death (2–4%) [23,24].
3.3. Intraluminal thrombotic occlusion
Obstruction, with resultant loss of ability to with-
draw and/or infuse material, is another complication 
related to IVAD. Such occlusion may lead to potentially 
significant delays in necessary treatment regimens 
as many of the patients are receiving medication 
that can only be administered via central access. This 
complication may be due to a variety of conditions, 
including mechanical obstruction, fibrin sheath for-
mation, drug precipitation and intraluminal thrombo-
sis occlusion [28–30]. Mechanical obstructions may 
include kinking of the catheter, malposition of the tip 
and the catheter being pinched against the first rib or 
clavicle [28,31]. The occurrence of fibrin sheath for-
mation is another reason for intraluminal obstruction. 
Fibrin may migrate into the lumen causing catheter 
obstruction. This topic will be discussed later in the 
paper. Deposition of either lipid or crystal may also 
cause catheter occlusion. Total parenteral nutrition 
is the major source of lipid precipitates, which can be 
cleared by instillation of 70% ethyl alcohol. Etoposide, 
calcium, diazepam, phenytoin and heparin may cause 
mineral drug precipitates, which can be treated with 
1 mL of 0.1% hydrochloric acid [28,32]. However, 
over 60% of catheter obstruction is due to thrombotic 
occlusion, which leads to the removal of the device in 
60–100% of cases before the development of effective 
therapy [2,4]. IVAD intraluminal thrombotic occlusion 
is caused by blood components in 1.7–3% of cases 
[4,6,28]. Without adequate volume or frequency of 
heparin injection, retrograde blood clots will develop 
inside the lumen, resulting in total occlusion.
3.4. Fibrin sheath
Fibrin sheath formation is an insidious problem that 
can plague essentially all central venous catheters. 
The formation may start as early as 24 hours after 
insertion and between 42% and 100% of catheters 
in place over 1 week may generate fibrin sheaths 
[33,34]. The term fibrin sheath refers to a sleeve 
of fibrin that surrounds the catheter from the tip to 
where it enters the vein. A fibrin sheath can form 
and encase the outside surface of the catheter. The 
sheath may cause a sac in the distal tip initially and 
extend downward closing over the tip of the cath-
eter. A flap-valve will be formed, allowing entry but 
preventing withdrawal of blood and fluid, resulting 
in partial occlusion [33,34]. This partial occlusion 
is also called persistent withdrawal occlusion (PWO) 
and typically manifests at the occurrence of fibrin 
sheath. This is of particular importance when large-
bore catheters are used for hemodialysis. However, 
its influence is trivial when IVADs are used for chemo-
therapy. Complete occlusion may occasionally occur 
if the fibrin adhering to the catheter migrates into 
the lumen. Although most fibrin sheaths are clini-
cally silent, their formation may promote and medi-
ate bacterial attachment and infection. Therefore, a 
catheter with a fibrin sheath may cause an increase 
in IVAD infection rate. Consequently, infected cath-
eters can be the source of positive blood cultures 
and fibrin sheath can enhance the propensity for 
persistent bacteremia [18,35]. In a few cases (2.6%), 
extravasation of fluid into the surrounding tissues 
can occur if a sheath solidly encases the IVAD from 
its tip to its venous entry point [33].
4. Diagnosis
4.1. RA thrombus
RA thrombi may be underdiagnosed because most 
of them are asymptomatic and a small thrombus is 
difficult to recognize by transthoracic echocardiog-
raphy [36]. Most RA thrombi were found by accident 
while evaluating heart function by echocardiography 
[14,17]. One case was noted on routine chest com-
puted tomography (CT) scan [37]. Transesophageal 
echocardiography (TEE) is a simple and effective diag-
nostic technique, which provides an unobstructed 
view of the cardiac structures and the great vessels 
[13,17,36]. Cohen et al evaluated the superiority of 
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TEE for detecting catheter-related RA thrombus in 
19 patients, while transthoracic echocardiography only 
found five (26%) of them. TEE not only better defined 
the size and mobility of the thrombus, it also provided 
a superior image of masses located in or near the 
SVC, inferior vena cava or in the RA appendage [16]. 
A similar outcome was also reported by Schwartzbard 
et al [38]. In their investigation, transthoracic echocar-
diography had a 60% false-negative rate for the evalu-
ation of RA thrombi and 100% misdiagnosis of RA 
appendage thrombi. Therefore, evaluation using TEE 
is needed whenever RA thrombus is suspected.
4.2. CVT
Although the occurrence of thrombotic symptoms is 
the best way to identify CVT, diagnosis is usually delayed 
after the patient develops symptoms of complete 
occlusion or infusional difficulties. This is because 
the clinical presentation of CVT is insidious in evo-
lution and is usually characterized by nonspecific 
symptoms [23]. Catheter-related CVT patients did not 
consistently demonstrate venous dilation or develop 
clinically recognizable venous collaterals, nor was 
regional swelling a uniform clinical feature [5]. In such 
a situation, recognition of early signs or symptoms of 
CVT does not seem to be easy.
There are several available modalities, such as chest 
radiography, contrast venography, ultrasonography, CT, 
magnetic resonance imaging (MRI) angiography and 
TEE, for evaluating suspected cases [23]. Chest radi-
ography can rule out the possibility of catheter tip 
malposition, kinking or fracture. Contrast venogra-
phy is used as the standard for diagnosis of large 
vessel occlusion in the upper venous system. It 
helps to assess the size and location of intramural 
thromboses accurately, and gives excellent visualiza-
tion of collaterals [3,24]. Although contrast venog-
raphy is a great tool for evaluating CVT, it is still too 
invasive for general survey such as TEE. CT and MRI 
provide excellent visualization and are noninvasive, 
although their high costs limit their use [23]. Although 
ultrasonography, especially color flow Doppler and 
compression ultrasonography, provides a convenient 
and noninvasive method for thrombosis diagnosis, 
its high sensitivity and specificity are only particular 
for upper-extremity DVT. Therefore, we can conclude 
that different tools have different advantages and 
limitations, and none of them can be widely used as 
the standard method at present.
4.3. Intraluminal thrombotic occlusion
To identify whether the device is occluded, a push-
pull technique can be used [29]. In this procedure, 
normal saline is used in an attempt to gently irrigate 
the catheter to see if installation of normal saline 
and/or blood aspiration is successful. If infusion of 
fluids and aspiration of blood is impossible, complete 
occlusion has occurred and is generally caused by 
clotted blood. If fluids can be infused but no blood 
can be aspirated, this is called partial occlusion or 
PWO, which is usually caused by fibrin sheath for-
mation [39,40]. A more precise definition of “cannot 
aspirate” is the inability to withdraw 3 mL of blood 
from the device [31,41]. To rule out the possibility of 
malpositioning of the catheter, recent chest X-rays 
should be reviewed to verify the catheter tip loca-
tion [29,41]. In addition, occlusion caused by non-
hematologic factors, such as deposition of either lip-
ids or crystal, should also be considered. Check the 
medication administration to see whether any infu-
sate has been infused that may cause a precipitate 
[29]. Although Ponec et al believed radiographic con-
trast material injection is useful in determining the 
cause of obstruction and the type of therapy neces-
sary, contrast injection studies are often not readily 
available in clinical practice [31]. As a result, clinical 
catheter dysfunction is still the most popular way to 
diagnose device obstruction.
4.4. Fibrin sheath
Diagnosis of fibrin sheath formation is usually mani-
fested by catheter malfunction, especially PWO. To 
exclude anatomical obstruction, various physical 
maneuvers should be performed, such as changing 
the position of the patient’s arm and/or head while 
attempting aspiration. Fluoroscopy, a tool for seek-
ing catheter kinks or leaks, can be used if mechani-
cal cause is highly suspected. However, if definite 
diagnosis needs to be proven, contrast venography 
should be performed [34].
5. Management
5.1. RA thrombus
5.1.1. Surgical approach
For a symptomatic patient with a large mobile throm-
bus or persistent infection, surgical thrombectomy 
is strongly recommended (Table 2) [12,17]. These 
thrombi may threaten atrial or ventricular inflow and 
cause sudden death. Further, large-sized thrombi 
can be organized and contain calcifications, suggest-
ing that they are usually old and hard to resolve [12]. 
In some cases, with additional infection, antibiot-
ics alone are not sufficient. These thrombi should 
be surgically removed and the catheter should 
also be explanted [16–20]. Compared with medical 
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management, surgical thrombectomy and explan-
tation not only remove the thrombus and 
control the infection but also prevent the pos-
sibility of life-threatening complications [17].
5.1.2. Medical approach
Due to morbidity and mortality, only a few cases 
of RA thrombosis, most of them in children, 
have been treated by medical management 
(Table 3). A completely dissolved case without 
side effects was reported by Adamovich et al in a 
neonate after 5 days’ infusion of urokinase and 
prophylactic intravenous heparin with subcu-
taneous low-molecular-weight heparin (LMWH) 
[42]. Another successful pediatric case reported 
by Cesaro et al was treated with recombinant 
tissue plasminogen activator (rt-PA) (0.1 mg/kg/
hr for 12 hours) and heparin (10 IU/kg/hr for 
24 hours) for 6 days without significant side 
effects [43]. Korones et al believed that a small-
sized thrombus did not need any intervention, 
even though no regression was seen after 1 year, 
and that a moderate-sized thrombus only needed 
medication, such as warfarin, instead of sur-
gical thrombectomy [12]. Although RA throm-
bus is less menacing in pediatric patients, there 
were still several cases of failure that eventu-
ally needed surgical intervention [14,21]. In 
adults, medical treatment has been tried in 
only a few reported cases because it is believed 
that, even though antithrombotic agents may 
stabilize or regress catheter-related RA thrombi, 
anticoagulated patients remain at risk of pul-
monary embolism and need to receive surgical 
thrombectomy eventually [10,11,44].
5.1.3. Summary
Catheter-related RA thrombosis is a life-
threatening complication that may not be as 
rare as we previously thought if the catheter tip 
is inserted into the RA. Medical management 
may be indicated in pediatric patients with 
small- to moderately-sized thrombi. How ever, 
surgical thrombectomy is still considered the 
safest and most effective treatment for adults 
and also for children with large-sized thrombi.
5.2. CVT
5.2.1. Surgical approach
The handling of IVAD after CVT varies in the lit-
erature. Although medical antithrombotic treat-
ment was widely applied, most of the devices 
were still explanted; some were removed before 
treatment [5,6] and some were explanted after 
fibrinolytic, antithrombotic or anticoagulant 
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treatment failed [4,5,8]. The most common reason 
for explantation of IVAD is prevention of thrombosis 
progression, especially in the case of SVC syndrome. 
Other reasons are persistent pain, combined with a 
documented infection and extravasation. However, 
does SVC syndrome or any other complication related 
to CVT definitely disappear after explantation? A neg-
ative answer was first noted in Lokich et al’s study, 
when they noticed that withdrawal of IVAD rarely 
resolved the vascular occlusion [3]. Recently, to deter-
mine whether CVT can be self-limiting after explanta-
tion, 24 oncologic children undergoing port removal 
because of completion of therapy were enrolled in the 
study of Glaser et al [24]. Vessel patency was evalu-
ated by contrast venography, which showed abnor-
malities in 12 patients (50%), including three severe 
occlusions and nine occult. This trial revealed that the 
obstructed vessels may not recanalize even after IVAD 
removal. Wilimas et al followed up the catheter-related 
CVT by contrast-enhanced CT at least 2 months after 
catheter removal [45]. Surprisingly, the thrombus in 
several patients persisted as long as 30 months after 
catheter removal and did not recanalize. This result 
shows that the thrombotic lesions may be long-lasting 
or permanent. Therefore, surgical explantation may 
not consequentially solve the problems of CVT but 
may influence usability with respect to the advantages 
of IVAD in the treatment of cancer patients.
5.2.2. Medical approach
Antithrombotic treatment is necessary for all CVT 
patients with or without IVAD explantation. Removal 
of the device should be decided by clinical neces-
sity for venous access or by evidence of pulmonary 
embolism [5]. Although pulmonary embolism is con-
sidered a morbid complication, no case has been 
documented in the ongoing use group of IVAD with 
catheter-related CVT [5,22,25]. In a Letter to the 
Editor from Kroger et al, 42 patients (80%) with CVT 
received only heparin intravenously, with effective 
prolongation of the partial thromboplastin time, or 
LMWH subcutaneously without explantation [22]. The 
results showed that the devices could still be used 
for further application of chemotherapy and possible 
complications, such as pulmonary embolism, infec-
tions, or bleeding associated with the anticoagulation 
or caused by the puncture of subcutaneous collateral 
veins, were not observed. They suggested that anti-
coagulation should be maintained for 6–12 weeks. 
Recently, unfractionated heparin (UFH) and LMWH have 
been the most popular antithrombotic agents used 
for the treatment of catheter-related CVT.
5.2.2.1. UFH
Intravenous UFH is the initial treatment of choice 
for acute CVT. UFH can prevent clot propagation but 
cannot dissolve it. Therefore, recanalization may 
not develop. It can be given by continuous intrave-
nous infusion for 5–10 days, starting with a bolus of 
5000 IU followed by 30,000–35,000 IU/day, adjusted 
to achieve an activated partial thromboplastin time of 
1.5–2.5 times the control [46]. Patients who achieved 
therapeutic plasma concentrations of heparin had 
recurrence rates 15 times lower than those who 
did not reach the therapeutic range [46]. Long-term 
vitamin K antagonists and warfarin may also be given 
with UFH to prevent the propagation of thrombi 
[47]. However, UFH has a number of limitations that 
have restricted its use: unpredictable anticoagulant 
effects, inhibition of platelet aggregation, augmenta-
tion of vessel wall permeability, thrombocytopenia 
and potential bleeding complications.
5.2.2.2. LMWH
Recently, LMWHs have been used in the treatment of 
acute DVT and acute pulmonary embolism. LMWHs 
have theoretical advantages over UFH, including higher 
bioavailability, longer half-life and a more predictable 
antithrombotic effect. The antithrombotic activity of 
LMWHs is mainly based on the inactivation of factor 
Xa because of a reduced ability to inactivate factor 
IIa when compared with UFH.
To assess the efficacy of LMWHs, several rand-
omized trials have taken place since the early 1990s 
comparing LMWHs with standard heparin in the initial 
treatment of acute proximal venous thrombosis. In six 
recent studies, there were obvious reductions in the 
rate of recurrent venous thromboembolism between 
LMWH groups and UFH groups (Table 4) [48–51]. 
LMWHs not only prevented the recurrence of throm-
bosis but also helped with thrombus regression [48].
In addition to efficacy, LMWHs have many advan-
tages compared to UFH. Firstly, LMWHs can be admin-
istered subcutaneously in weight-adjusted, once or 
twice daily, doses without the need for laboratory mon-
itoring [46,47]. Due to their properties, most patients 
with CVT can be given LMWHs safely and accurately 
at home without hospitalization, increasing the con-
venience for the patient and reducing the cost to the 
health care system [51,52]. Secondly, LMWHs have 
minimal interaction with platelets and have potentially 
more antithrombotic rather than hemorrhagic activity 
compared with UFH. Further, the incidence of heparin-
induced thrombocytopenia is less with LMWHs [46]. 
Thirdly, the major bleeding rate and mortality rate 
associated with LMWHs were significantly lower than 
those associated with UFH, and LMWHs may exert an 
inhibitory effect on tumor growth in cancer patients 
[48,53]. Therefore, we can conclude that LMWHs have 
better effectiveness than UFH in the prevention of 
recurrent episodes of DVT, better safety with respect 
to the occurrence of major bleeding, and better cost-
effectiveness and convenience facilitating outpatient 
management of catheter-related CVT.
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5.2.2.3. Fibrinolytic agents
Fibrinolytic agents, such as streptokinase, urokinase 
and rt-PA, are usually effective for the lysis of fresh 
thrombi. Therefore, resolution of thrombi is more 
significant in acute occlusions than in CVT, which 
is always detected after a period of time. Although 
some studies mentioned their usage, antithrombotic 
agents are still the first choice [5,25].
5.3. Intraluminal thrombotic occlusion
5.3.1. Surgical approach
It is certain that surgical explantation of the device 
should only be considered after fibrinolytics have 
failed or therapy has been terminated because of its 
minor severity and the high success rate of medical 
treatment [5,6,39].
5.3.2. Medical approach
Fibrinolytic agents, such as rt-PA, urokinase and strep-
tokinase, have been used in recent decades to lyse 
intraluminal thrombi, to restore device patency and 
to avoid catheter removal. Although some complica-
tions, such as bleeding, hypersensitivity reactions, 
arrhythmias, hypotension, fever, nausea or vomit-
ing, may be associated with their usage, intraluminal 
installation of fibrinolytic agents is still considered 
the safest and most effective therapy for the treat-
ment of IVAD intraluminal thrombotic occlusions.
5.3.2.1. rt-PA
Alteplase is the most popular and effective rt-PA used 
in the treatment of thrombotic occlusion. It is a ser-
ine protease that activates plasminogen to plasmin in 
the cleavage of thrombus-bound fibrin. Alteplase was 
primarily used for the treatment of acute myocardial 
infarction, pulmonary embolism and acute ischemic 
stroke, and has recently been used in the therapy of 
occluded IVAD. In adult patients, 2 mg alteplase in 
2 mL sterile water may be injected into the occluded 
catheter. Restoration of function is assessed 30–120 
minutes later [29,31,41,54,55]. If function is not 
restored, a second attempt with the same dose is 
performed [31,41,54–56]. Surprisingly, the propor-
tion of patients in whom successful treatment was 
achieved after a single dose ranged from 64% to 
86%, and success was achieved in 81–94% after 
two doses (Table 3). Alteplase can also be used in 
pediatric oncologic patients with dysfunctional IVAD. 
Indwelling 0.5 mg/1.0 mL alteplase once or twice 
obtained an 88–97% success rate without significant 
adverse events [56,57]. Alteplase not only converts 
the entrapped plasminogen to plasmin, resulting in 
local fibrinolysis, but also provides better efficacy 
in restoring occluded IVAD function and faster dis-
solving of thrombi than urokinase [29,41,54,55]. In 
addition, alteplase has the advantages of a low inci-
dence of allergic reactions (< 0.02%) and no docu-
mented reports of sustained antibody formation after 
administration [5].
Although small dose alteplase is so far not com-
mercially available, large dose alteplase can be split 
into unit doses and cryopreserved at –20°C for 
30 days [29]. Reconstruction to small dose aliquots 
makes this a cost-effective solution without compro-
mising safety and efficacy [29,40,41,56]. However, 
the production of a single-dose rt-PA vial is still needed, 
not only for small institutions but also as a convenient 
and safe agent for oncologic patients.
5.3.2.2. Urokinase
Previously, urokinase, a product from primary cell 
cultures of kidney cells harvested after death from 
human neonates, was suggested by the United States 
Food and Drug Administration (FDA) as a clinical path-
way for IVAD occlusion. However, in January 1999, 
the FDA identified problems with the manufacturing 
process of urokinase. Like all human-based biological 
products, it has the potential to spread infectious dis-
ease [40]. In 1999, the FDA reported on microorgan-
ism contamination of urokinase and issued a warning 
about variations in quality control during manufac-
ture, recommending that urokinase be restricted to 
specific patients in whom the physician has judged 
urokinase to be critical to the clinical situation [58].
Table 4 — Comparison of the efficacy and safety of treatment of central vein thrombosis with low-molecular-weight 
heparins (LMWHs) and unfractionated heparin (UFH)
Authors [Ref]
 LMWHs/UFH
 Rate of recurrent venous Rate of major 
Rate of death (%)
 thromboembolism (%) bleeding (%)
Hull et al [48] 2.8/6.9 0.5/5.0* 4.7/9.6*
Prandoni et al [49] 7/14 1.1/3.5 7/14
Dolovich et al [50] 4.3/5.1 1.5/2.5 4.9/6.5*
Levine et al [51] 5.3/6.7 1.2/2.0 5.3/6.7
Koopman et al [52] 6.9/8.6 0.5/2.0 6.9/8.1
*p < 0.05.
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5.3.2.3. Streptokinase
Although streptokinase can resolve occlusions without 
hemorrhagic side effects or coagulation changes, aller-
gic reactions and the induction of antibody formation 
limits its usefulness. Fever and shivering (1–4%), and 
anaphylactic reactions (0.1%) occurred when intra-
venous streptokinase was given [29]. In addition, 
inactivated antibodies resulting from patients’ prior 
exposure to streptokinase or streptococcal infections 
may potentially increase the risk of allergic response 
[40]. An initial (1.5 million IU) dose of streptokinase 
may produce neutralizing antibodies that persist for 
up to 12 weeks that could preclude prolonged or 
follow-up administration. These risks/issues led to 
the restriction of its usage [29,59]. Therefore, the 
producers of streptokinase, AstraZeneca, released 
an Important Safety Information letter on strep-
tokinase in December 1999. They warned that there 
is a risk of significant allergic reactions and that 
streptokinase is not indicated for restoration of IVAD 
patency [59].
5.4. Fibrin sheath
5.4.1. Surgical approach
Although fibrin sheath formation is the most common 
type of catheter-related thrombosis, life-threatening 
complications rarely occur. Fibrin sheath formation 
without device malfunction needs no treatment. If 
PWO or complete occlusion is exhibited, most of 
the problems can be solved by fibrinolytics. In con-
trast, device removal is not only high in cost but also 
delays the patient’s treatment [33]. In addition, a 
near-fatal case of air embolism was reported after 
surgical explantation of the device. It is speculated 
that fibrin sheath formation might provide a chan-
nel for air embolism after catheter removal [60]. 
Therefore, surgical management is not suggested for 
fibrin sheath treatment.
5.4.2. Medical approach
PWO, complete occlusion and extravasation of the 
device caused by fibrin sheath formation can all be 
lysed by fibrinolytics [32,40]. The formation of the 
fibrin that causes PWO may take a longer period of 
time than fresh thrombi that induce complete occlu-
sion. Therefore, clearance of PWO may be more dif-
ficult than clearing complete occlusion. Davis et al 
suggested that alteplase be used in partially blocked 
catheters, at a dosage of 0.5 mg/mL, 1 mg/mL and 
2 mg/mL [40]. Whigham et al used 1 mg/mL tPA 
injected into the catheter followed by 0.4 mL ster-
ile saline for 15 minutes three times until successful 
[34]. If catheter clearance was not achieved after the 
third dose, a fourth dose was infused and allowed to 
remain overnight: 92.9% of fibrin sheath with PWO 
were dissolved and confirmed by contrast venogra-
phy, requiring an average dose of 2.29 mg.
5.4.3. Summary
Catheter-related IVAD fibrin sheath formation needs 
no invasive treatment. However, fibrinolytic agents 
are the best choice for a non-functioning device.
6. Conclusion
Without proper diagnosis of the exact etiology, IVADs 
with related thromboses have been removed before 
attempting any medical treatment. However, our evi-
dence-based review clearly demonstrates that use 
of fibrinolytic agents through the device is the best 
practice for the two most common etiologies of IVAD-
related thromboses, i.e. fibrin sheath formation and 
intraluminal thrombotic occlusion. Device explanta-
tion is obviously not indicated. Furthermore, anti-
thrombotic agent infusion is undoubtedly essential 
for the management of CVT, while the benefit of 
removing the device is still in question. Among the 
four locations of IVAD-related thromboses, RA throm-
bus is an absolute surgical indication due to its poten-
tially life-threatening outcome. Prompt thrombectomy 
is considered the safe and effective treatment for 
adults and for children with large-size thrombi. In 
conclusion, our review suggests that an exact diag-
nosis of the location of the IVAD-related thrombosis 
is indispensable so that a proper treatment strategy 
can be implemented to prolong the lifespan of the 
IVAD and reduce the complications associated with 
thrombosis.
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